Featured Vascular Anomalies Trials

EPIK-P2 (CBYL719F12201) / EPIK-P2: A Phase II double-blind study with an upfront, 16- week randomized, placebo-controlled period, to assess the efficacy, safety and pharmacokinetics of alpelisib (BYL719) in pediatric and adult patients with PIK3CA-related overgrowth spectrum (PROS)

  • Subjects will be identified from the population of patients diagnosed with PIK3CA-related Overgrowth Spectrum (PROS), receiving medical care from the Cancer and Hematology Center and Vascular Anomalies Center at Texas Children’s Hospital. Up to ten (10) patients will be enrolled overall.
  • Participants will be enrolled into two age groups: Group 1: ≥ 18 years old and Group 2: 6-17 years old.
  • All Sexes are Eligible

MK705-006 / A Multicenter, Open-label, Phase 2 Extension Trial to Study the Long-Term Safety in Participants With PROS or Proteus Syndrome Who Are Currently Being Treated with Miransertib in Other Studies

  • Subjects will include participants with PROS or PS who are currently receiving miransertib as part of Study MK-7075-002 (also known as the MOSAIC study or ArQule’s compassionate use/expanded access program. At our site participants will enter this study as an extension of the ARQ MOSAIC study.
  • All Sexes are Eligible

Anticoagulation Effects on Quality of Life in Patients with Slow-flow Vascular Malformations

  • Presence of a slow-flow vascular malformation
  • ≥2 years old to 99 years old
  • Determined to need and eligible for anticoagulation therapy at the discretion of the treating physician per standard of care
  • Informed consent provided, and if applicable, child assent provided
  • All Sexes are Eligible

For a complete list of clinical trials offered at Texas Children's Hospital, visit clinicaltrials.gov

Interested in learning more? Frequently asked questions about clinical trials